Almost six years after the anthrax attacks, the US BioShield Program has singularly failed to add new products to the nation's stockpile.
Volume 25 Issue 6, June 2007
FDA left no doubt after a May meeting that it plans to continue pressuring sponsors of erythropoiesis-stimulating agents for more definitive clinical data.
News in Brief
A self-made billionaire and serial entrepreneur of numerous medical device and biotech ventures, Mann has been exemplary in his philanthropy. This has not meant that his Alfred E. Mann Foundation for Biomedical Engineering (AMFBE) has been without its critics.
News & Views
Improving the success rate of proteome analysis by modeling protein-abundance distributions and experimental designs
Truly comprehensive proteome analysis is highly desirable in systems biology and biomarker discovery efforts. But complete proteome characterization has been hindered by the dynamic range and detection sensitivity of experimental designs, which are not adequate to the very wide range of protein abundances. Experimental designs for comprehensive analytical efforts involve separation followed by mass spectrometry–based identification of digested proteins. Because results are generally reported as a collection of identifications with no information on the fraction of the proteome that was missed, they are difficult to evaluate and potentially misleading. Here we address this problem by taking a holistic view of the experimental design and using computer simulations to estimate the success rate for any given experiment. Our approach demonstrates that simple changes in typical experimental designs can enhance the success rate of proteome analysis by five- to tenfold.